Committee Member	Employment	Consultant	Speakers Bureau	Ownership/Partnership/Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Paul A. Heidenreich (Chair)	Stanford VA Palo Alto Health Care System–Professor of Medicine	None	None	None	None	None	None
Gregg C. Fonarow* (Vice Chair)	UCLA Medical Center–Professor of Medicine	Abbott† Amgen Astra Zeneca CHF Solutions Janssen Pharmaceuticals Medtronic Merck Novartis†	None	None	Medtronic Novartis†	Boston Scientific	None
Khadijah Breathett‡	UA College of Medicine, Tucson–Assistant Professor of Medicine	None	None	None	None	None	None
Corrine Y. Jurgens	Boston College, School of Nursing–Associate Professor	None	None	None	None	None	None
Barbara A. Pisani*	Wake Forest Baptist Medical Center–Medical Director, Heart Failure, Heart Transplant, Mechanical Circulatory Support	None	None	None	None	Abbott§ Amgen–GALACTIC HF Trial (PI) Medtronic§ Novartis–PIONEER Trial (PI) Sanofi-Aventis–SOLOIST Study (PI)	None
Bunny J. Pozehl	University of Nebraska Medical Center, Omaha Division–Professor College of Nursing	None	None	None	None	None	None
John A. Spertus*	Saint Luke’s Mid America Heart Institute–Director, Health Outcomes Research; University of Missouri-Kansas City–Professor	Amgen AstraZeneca† Bayer Boehringer Ingelheim† Janssen Pharmaceuticals† KCCQ† Merck† Novartis†	None	None	None	Abbott AstraZeneca UK Limited Outcomes Instruments† Medtronic Novartis†	None
Kenneth G. Taylor‖	Piedmont Heart Institute–Heart Failure and Interventional Cardiologist	None	None	None	None	None	None
Jennifer T. Thibodeau*	University of Texas Southwestern Medical Center–Associate Professor; Director, Heart Failure; Interim Section Chief, Heart Failure, Cardiac Transplantation, Ventricular Assist Devices	None	None	None	Novartis	None	None
Clyde W. Yancy	Northwestern University, Feinberg School of Medicine–Magerstadt Professor of Medicine; Division of Cardiology–Chief	None	None	None	None	Abbott§	None
Boback Ziaeian	UCLA David Geffen School of Medicine–Assistant Professor; VA Greater Los Angeles Healthcare System–Director of Telecardiology	None	None	None	None	None	None

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document or makes a competing drug or device addressed in the document; or c) the person, or a member of the person’s household, has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

^*Writing committee members were excluded from voting on sections to which their specific relationships with industry and other entities may apply. Dr. Fonarow was excluded from voting on PM-4, PM-5, PM-6, PM-7, PM-8, PM-9, PM-10, PM-12, PM-13, and SM-1. Dr. Pisani was excluded from voting on PM-5, PM-6, PM-8, PM-12, and PM-13. Dr. Spertus was excluded from voting on PM-2, PM-3, PM-4, PM-5, PM-6, PM-7, PM-8, PM-9, PM-10, PM-12, PM-13, QM-2, QM-3, and SM-1. Dr. Thibodeau was excluded from voting on PM-5, PM-6, and PM-8.

^†Significant relationship.

^‡CMS reported payments to Dr. Breathett in 2019 related to food, beverage, travel, and lodging for Abbott; however, she disagrees with this report. Dr. Breathett was not the lead author on any measures.

^§No financial benefit.

^‖CMS reported a food and beverage payment from Novartis to Dr. Taylor in 2019, however, he disagrees with this report. Novartis has marked the food and beverage entry for deletion. Dr. Taylor was not the lead author on any measures.

ACC indicates American College of Cardiology; AHA, American Heart Association; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; PI, principal investigator; UA, University of Arizona; UCLA, University of California, Los Angeles; UK, United Kingdom; and VA, Veterans Affairs.